Investors Mutual’s Daniel Moore says there aren’t too many ASX-listed companies like blood plasma giant CSL that can compound their earnings at such a rate.
Already a subscriber?When sleep apnoea device manufacturer ResMed’s share price slumped almost 40 per cent from peak to trough last year on fears that weight loss wonder drug Ozempic would shrink the market for people seeking treatment for sleep disorders, Investors Mutual’s Daniel Moore was a buyer.
“Our research gave us the opinion that the Ozempic drugs would have limited impact on ResMed’s business,” the fund manager said. “It’s an industry leader.” If a business is higher quality, it should demand a higher valuation – but that doesn’t preclude value investors from owning it., but Moore says despite the stock trading at a multiple similar to the notoriously expensive Commonwealth Bank, CSL has been able to grow its earnings by around 15 per cent annually.“Even when you look at some of the tech companies, their earnings growth is not much higher than CSL, but they trade on multiples considerably higher,” he says.
“A great lesson we learned from Anton was writing letters to boards is a very effective way of sharpening directors’ focus on what shareholders want,” Moore says. “Letters to boards get minted in board meetings, and if they ignore those letters, there’s a potential liability on directors, so they really pay attention.”
Telstra, he says, has the most scale and the superior network. “They can charge higher prices. They’ve got a commanding position.”Investors Mutual’s Australian Shares Fund sealed a total return of 12.4 per cent in the year to September 30. That’s below the ASX 300 Accumulation Index’s return of 21.7 per cent. Even so, the fund has outperformed since its inception in June 1998, returning 9.7 per cent annually compared to the benchmark’s 8.9 per cent.
United States Latest News, United States Headlines
Similar News:You can also read news stories similar to this one that we have collected from other news sources.
ASX 200 LIVE: ASX to drop, $A slides as US outlook worries riseRecession fears resurge after US data. CEO Peter King to depart Westpac in December. Nasdaq sinks more than 2 per cent. Follow here for more.
Read more »
ASX 200 LIVE: ASX to rise after Wall Street rebounds, consumer confidence data pendingAustralian shares are set to open higher. The Dow paced a modest buy-the-dip rally. Consumer and business confidence data pending. Follow updates here.
Read more »
ASX 200 LIVE: ASX to edge up, RBA speech, US August CPI awaitedMining and oil stocks play tug-o-war with ASX. Techs paced gains in New York. ASX gets new chairman. Melbana Energy soars 40pc on takeover offer. Follow for more
Read more »
ASX 200 LIVE: ASX to fall, S&P 500 ends modestly lower after Fed cuts ratesASX shrugs off poor pre-market trading to chart new high. US stocks closed lower after Jerome Powell dashed hopes for aggressive rate cuts. Follow updates here.
Read more »
ASX 200 LIVE: ASX to rise, S&P 500 closes at a record highLocal shares to rise after Wall St records reset. BHP, Rio rally in New York. $A leaps as does bitcoin. Myer results pending. Follow updates here.
Read more »
ASX 200 LIVE: ASX to slip, RBA rate decision pendingShares are set to open down; RBA expected to hold rates steady, decision at 2.30pm AEST; gold resets record. Follow updates here.
Read more »